Clinical Trials Logo

Clinical Trial Summary

Study Hypothesis: The peri-operative enteral administration of a proprietary immune-enhancing feed (IMPACT) will not reduce post-operative infective complications in patients undergoing major surgery for squamous cell carcinoma of the Head and neck (SCCHN).

Patients who present with SCCHN for whom surgery is the recommended treatment will, assuming they fulfill the eligibility criteria, be block randomised into a two-group, double-blind randomised controlled trial. One group will receive IMPACT, the other an iso-caloric, iso-nitrogenous control feed for 5 days pre and 7 days post-operatively. In both groups patients will be fed enterally. The feeds will be prepared in identical bottles to facilitate blinding. Primary outcome measures include major systemic infection, whilst secondary outcome measures include local infection and length of hospital stay. Follow-up will be for 30 days postsurgery.


Clinical Trial Description

As above ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01314755
Study type Interventional
Source Liverpool University Hospitals NHS Foundation Trust
Contact
Status Completed
Phase N/A
Start date November 2003
Completion date July 2008

See also
  Status Clinical Trial Phase
Recruiting NCT02734537 - Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Phase 2
Not yet recruiting NCT06137378 - European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] Phase 2
Recruiting NCT05333523 - Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. Phase 3
Not yet recruiting NCT05832593 - Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.
Recruiting NCT05293327 - IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate
Active, not recruiting NCT05551117 - A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors Phase 2
Terminated NCT02582008 - Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Early Phase 1
Recruiting NCT05136196 - BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Phase 2
Active, not recruiting NCT04030455 - Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer Phase 2
Active, not recruiting NCT03258554 - Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Phase 2/Phase 3
Not yet recruiting NCT06084845 - Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Phase 2